{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:02:08Z","timestamp":1790262128717,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370358"],"award-info":[{"award-number":["82370358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470361"],"award-info":[{"award-number":["82470361"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400495"],"award-info":[{"award-number":["82400495"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr. Diabetes"],"DOI":"10.1038\/s41387-026-00433-x","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:06:18Z","timestamp":1783130778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subgroup-specific cardiovascular effects of intensive lifestyle intervention: a causal forest analysis in adults with type 2 diabetes and overweight\/obesity"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-2128","authenticated-orcid":false,"given":"Xingfeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjie","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8196-5183","authenticated-orcid":false,"given":"Lixiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-4447","authenticated-orcid":false,"given":"Menghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxue","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"433_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41569-020-00465-5","volume":"18","author":"ACT Ng","year":"2021","unstructured":"Ng ACT, Delgado V, Borlaug BA, Bax JJ. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol. 2021;18:291\u2013304.","journal-title":"Nat Rev Cardiol"},{"key":"433_CR2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial. Jama. 2021;325:1403\u201313.","journal-title":"Jama"},{"key":"433_CR3","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","volume":"84","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024;84:1587\u2013602.","journal-title":"J Am Coll Cardiol"},{"key":"433_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia"},{"key":"433_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"key":"433_CR6","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.2337\/dc19-0776","volume":"42","author":"TI de Vries","year":"2019","unstructured":"de Vries TI, Dorresteijn JAN, van der Graaf Y, Visseren FLJ, Westerink J. Heterogeneity of treatment effects from an intensive lifestyle weight loss intervention on cardiovascular events in patients with type 2 diabetes: data from the look AHEAD trial. Diab Care. 2019;42:1988\u201394.","journal-title":"Diab Care"},{"key":"433_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diab Endocrinol. 2016;4:913\u201321.","journal-title":"Lancet Diab Endocrinol"},{"key":"433_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101451","volume":"49","author":"M Liu","year":"2022","unstructured":"Liu M, Huang R, Xu L, Zhang S, Zhong X, Chen X, et al. Cardiovascular effects of intensive lifestyle intervention in adults with overweight\/obesity and type 2 diabetes according to body weight time in range. EClinicalMedicine. 2022;49:101451.","journal-title":"EClinicalMedicine"},{"key":"433_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0197-2456(03)00064-3","volume":"24","author":"DH Ryan","year":"2003","unstructured":"Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610\u201328.","journal-title":"Control Clin Trials"},{"key":"433_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/oby.2006.84","volume":"14","author":"TA Wadden","year":"2006","unstructured":"Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, Williamson D, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14:737\u201352.","journal-title":"Obesity"},{"key":"433_CR11","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1073\/pnas.1510489113","volume":"113","author":"S Athey","year":"2016","unstructured":"Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci USA. 2016;113:7353\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"433_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/1740774511405858","volume":"8","author":"JA Wesche-Thobaben","year":"2011","unstructured":"Wesche-Thobaben JA. The development and description of the comparison group in the Look AHEAD trial. Clin trials (Lond, Engl). 2011;8:320\u20139.","journal-title":"Clin trials (Lond, Engl)"},{"key":"433_CR13","doi-asserted-by":"crossref","unstructured":"Buuren SV G-OK. MICE: Multivariate Imputation by Chained Equations in R. J Statistical Software. 2011;45.","DOI":"10.18637\/jss.v045.i03"},{"key":"433_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S2213-8587(17)30176-6","volume":"5","author":"A Baum","year":"2017","unstructured":"Baum A, Scarpa J, Bruzelius E, Tamler R, Basu S, Faghmous J. Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. Lancet Diab Endocrinol. 2017;5:808\u201315.","journal-title":"Lancet Diab Endocrinol"},{"key":"433_CR15","doi-asserted-by":"crossref","unstructured":"B\u0105k-Sosnowska M, Gruszczy\u0144ska M, Wyszomirska J, Daniel-Siela\u0144czyk A. The influence of selected psychological factors on medication adherence in patients with chronic diseases. Healthcare. 2022;10.","DOI":"10.3390\/healthcare10030426"},{"key":"433_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1037\/hea0000547","volume":"37","author":"CR Pacanowski","year":"2018","unstructured":"Pacanowski CR, Linde JA, Faulconbridge LF, Coday M, Safford MM, Chen H, et al. Psychological status and weight variability over eight years: results from Look AHEAD. Health Psychol. 2018;37:238\u201346.","journal-title":"Health Psychol"},{"key":"433_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2337\/dc23-1727","volume":"47","author":"C Zu","year":"2024","unstructured":"Zu C, Liu M, Su X, Wei Y, Meng Q, Liu C, et al. Association of body weight time in target range with the risk of kidney outcomes in patients with overweight\/obesity and type 2 diabetes mellitus. Diab Care. 2024;47:371\u20138.","journal-title":"Diab Care"},{"key":"433_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101420","volume":"48","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li F, Chu C, Zhang X, Zhang XY, Liao YY, et al. Early life body mass index trajectories and albuminuria in midlife: A 30-year prospective cohort study. EClinicalMedicine. 2022;48:101420.","journal-title":"EClinicalMedicine"},{"key":"433_CR19","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117-s314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"433_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.annepidem.2020.12.004","volume":"55","author":"K Inoue","year":"2021","unstructured":"Inoue K, Streja E, Tsujimoto T, Kobayashi H. Urinary albumin-to-creatinine ratio within normal range and all-cause or cardiovascular mortality among U.S. adults enrolled in the NHANES during 1999-2015. Ann Epidemiol. 2021;55:15\u201323.","journal-title":"Ann Epidemiol"},{"key":"433_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s11255-023-03499-z","volume":"55","author":"ZW Yang","year":"2023","unstructured":"Yang ZW, Fu YB, Wei XB, Fu BQ, Huang JL, Zhang GR, et al. Optimal threshold of urinary albumin-to-creatinine ratio (UACR) for predicting long-term cardiovascular and noncardiovascular mortality. Int Urol Nephrol. 2023;55:1811\u20139.","journal-title":"Int Urol Nephrol"},{"key":"433_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1210\/clinem\/dgad645","volume":"109","author":"C Zeng","year":"2024","unstructured":"Zeng C, Liu M, Zhang Y, Deng S, Xin Y, Hu X. Association of urine albumin to creatinine ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2024;109:1080\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"433_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1064665","volume":"13","author":"Z Gao","year":"2022","unstructured":"Gao Z, Zhu Y, Sun X, Zhu H, Jiang W, Sun M, et al. Establishment and validation of the cut-off values of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio for diabetic kidney disease: A multi-center, prospective cohort study. Front Endocrinol. 2022;13:1064665.","journal-title":"Front Endocrinol"},{"key":"433_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101420","volume":"49","author":"J Niu","year":"2023","unstructured":"Niu J, Zhang X, Li M, Wu S, Zheng R, Chen L, et al. Risk of cardiovascular disease, death, and renal progression in diabetes according to albuminuria and estimated glomerular filtration rate. Diab Metab. 2023;49:101420.","journal-title":"Diab Metab"},{"key":"433_CR25","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148:1636\u201364.","journal-title":"Circulation"},{"key":"433_CR26","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386:2024\u201334.","journal-title":"N Engl J Med"},{"key":"433_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01798-4","volume":"22","author":"P Gourdy","year":"2023","unstructured":"Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22:79.","journal-title":"Cardiovasc Diabetol"},{"key":"433_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.kint.2022.09.012","volume":"103","author":"EL Fu","year":"2023","unstructured":"Fu EL, Kutz A, Desai RJ. Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown. Kidney Int. 2023;103:30\u20133.","journal-title":"Kidney Int"},{"key":"433_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613\u201326.","journal-title":"Lancet"},{"key":"433_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/01621459.2017.1319839","volume":"113","author":"S Wager","year":"2018","unstructured":"Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. J Am Stat Assoc. 2018;113:1228\u201342.","journal-title":"J Am Stat Assoc"},{"key":"433_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.kint.2023.08.008","volume":"104","author":"TG Harrison","year":"2023","unstructured":"Harrison TG, Tonelli M. Measuring albuminuria or proteinuria: does one answer fit all?. Kidney Int. 2023;104:904\u20139.","journal-title":"Kidney Int"},{"key":"433_CR32","doi-asserted-by":"crossref","unstructured":"Sallsten G, Barregard L. Variability of Urinary Creatinine in Healthy Individuals. Int J Environ Res Public Health. 2021;18.","DOI":"10.3390\/ijerph18063166"}],"container-title":["Nutrition & Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-026-00433-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-026-00433-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-026-00433-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:02:29Z","timestamp":1790258549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-026-00433-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1038\/s41387-026-00433-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6186612\/v1","asserted-by":"object"}]},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The data used in this study were obtained from the LOOK AHEAD public database. These data have been previously de-identified and are available for research use under ethical approval from the Ottawa Health Science Network Research Ethics Board. Therefore, our study did not require additional ethical approval.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"39"}}